BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Masoumi-Moghaddam S, Amini A, Wei AQ, Robertson G, Morris DL. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer. Oncotarget 2015;6:28491-501. [PMID: 26143638 DOI: 10.18632/oncotarget.4427] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Y, Zhou X, He Y, Liao C. SLC6A1-miR133a-CDX2 loop regulates SK-OV-3 ovarian cancer cell proliferation, migration and invasion. Oncol Lett 2018;16:4977-83. [PMID: 30250563 DOI: 10.3892/ol.2018.9273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Fahmi MN, Pradjatmo H, Astuti I, Nindrea RD. Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2021;22:315-23. [PMID: 33639643 DOI: 10.31557/APJCP.2021.22.2.315] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E, Vergote I, Coosemans A. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol 2018;150:31-7. [PMID: 29751991 DOI: 10.1016/j.ygyno.2018.05.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
4 Zhou L, Luo W. Vascular endothelial growth factor-targeted paclitaxel-loaded liposome microbubbles and inhibition of human epidermoid-2 cell proliferation. Head Neck 2017;39:656-61. [PMID: 28106938 DOI: 10.1002/hed.24648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
5 Andorfer P, Heuwieser A, Heinzel A, Lukas A, Mayer B, Perco P. Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer. BMC Syst Biol 2016;10:33. [PMID: 27090655 DOI: 10.1186/s12918-016-0278-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
6 Camerin GR, Brito AB, Vassallo J, Derchain SF, Lima CS. VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients. Future Oncol 2017;13:409-14. [PMID: 27780361 DOI: 10.2217/fon-2016-0299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
7 Dalal V, Kumar R, Kumar S, Sharma A, Kumar L, Sharma JB, Roy KK, Singh N, Vanamail P. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients. Clin Chim Acta 2018;482:27-32. [PMID: 29572186 DOI: 10.1016/j.cca.2018.03.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
8 Yeung TL, Leung CS, Li F, Wong SS, Mok SC. Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules 2016;6:3. [PMID: 26751490 DOI: 10.3390/biom6010003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
9 Xu X, Deng F, Lv M, Chen X. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer. Arch Gynecol Obstet 2017;295:451-8. [PMID: 27913927 DOI: 10.1007/s00404-016-4256-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
10 Reed NS, Sadozye AH. Update on chemotherapy in gynaecological cancers. Obstet Gynecol 2016;18:182-8. [DOI: 10.1111/tog.12270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]